• In late April 2026, GE HealthCare Technologies reported first-quarter 2026 results showing revenue rising to US$5.13 billion from US$4.78 billion a year earlier, while net income declined to US$389 million and basic earnings per share fell to US$0.85 as profitability came under pressure.
• Alongside the earnings miss and reduced full-year profit outlook, the company reshaped its portfolio and leadership by creating a new US$14.60 billion Advanced Imaging Solutions segment, advancing AI- and cloud-enabled imaging capabilities, and progressing its manganese-based MRI contrast agent mangaciclanol into Phase 2/3 trials under FDA Fast Track designation.
• We’ll now examine how the cut to full-year profit guidance amid supply chain and cost pressures may influence GE HealthCare’s investment narrative.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

GE HealthCare Technologies Investment Narrative Recap

To own GE HealthCare, you need to believe its core imaging and diagnostics franchise and AI-enabled ecosystem can support steady, if unspectacular, growth even when margins come under strain. The Q1 2026 profit miss and softer full year guidance highlight that supply chain costs and tariffs are now the most immediate risk, while the key near term catalyst remains execution on new product uptake and integration of recent acquisitions; this quarter’s news reinforces rather than transforms that story.

Among recent developments, the launch of the manganese based MRI contrast agent mangaciclanol into Phase 2/3 trials under FDA Fast Track status stands out, given GE HealthCare’s focus on pharmaceutical diagnostics and recurring revenue. While clinical and regulatory outcomes are uncertain, this program sits squarely within the existing catalyst of expanding high impact products that can deepen the company’s role across imaging workflows and complement its broader push into AI and cloud enabled solutions.

However, against that opportunity, the scale of tariff and supply chain pressure now feeding into reduced 2026 profit guidance is something investors should be aware of as they weigh...

GE HealthCare Technologies' narrative projects $23.7 billion revenue and $2.7 billion earnings by 2029. This requires 4.8% yearly revenue growth and a roughly $0.6 billion earnings increase from $2.1 billion today.

Uncover how GE HealthCare Technologies' forecasts yield a $90.74 fair value, a 49% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community currently value GE HealthCare between US$80.32 and US$101.08 per share, highlighting a wide spread of expectations. You should weigh those views against the recent guidance cut driven by tariffs and supply chain costs, which brings the near term earnings risk into sharper focus and makes it important to compare several independent scenarios for the business.

Explore 4 other fair value estimates on GE HealthCare Technologies - why the stock might be worth just $80.32!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your GE HealthCare Technologies research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free GE HealthCare Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate GE HealthCare Technologies' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our top stock finds are flying under the radar-for now. Get in early:

• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.